XyloCor’s cardiovascular gene therapy XC001 passes Phase 1 with promising results
XyloCor Therapeutics, Inc., a company specializing in the development of gene therapies for cardiovascular diseases, announced that the Phase 1 findings of its clinical trial ... Read More
XyloCor reveals promising 12-month data from Phase 2 Trial of XC001
XyloCor Therapeutics, a clinical-stage biopharmaceutical company focusing on novel gene therapies for cardiovascular diseases, has revealed encouraging 12-month data from the Phase 2 section of ... Read More